Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

Cancer

Volumn 113, Issue 10, 2008, Pages 2734-2741

  Wang, Michael ^a   Fayad, Luis ^a   Cabanillas, Fernando ^b   Hagemeister, Fredrick ^a   McLaughlin, Peter ^a   Rodriguez, Maria A ^a   Kwak, Larry W ^a   Zhou, Yuhong ^c   Kantarjian, Hagop ^a   Romaguera, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Auxilio Mutuo Hospital   (Puerto Rico)

^c FUDAN UNIVERSITY   (China)

Author keywords

Hyper CVAD; Mantle cell lymphoma; Response rates; Rituximab; Survival rates

Indexed keywords

BLEOMYCIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VALACICLOVIR; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; SENSORY DYSFUNCTION; SENSORY LOSS; STEM CELL TRANSPLANTATION; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; SALVAGE THERAPY; VINCRISTINE;

EID: 56049111424     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23880     Document Type: Article

References (34)

1. Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol. 1989;7:365-380.
2. Norton AJ, Mathews J, Pappa V, et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20 year period. Ann Oncol. 1995;6:249-256.
3. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067-2078.
4. Teodorovic I, Pittaluga S, Kluinnelemans JC, et al. Efficacy of 4 different regimens in 64 mantle cell lymphoma cases. Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol. 1995;13:2819-2826.
5. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphomas. Ann Oncol. 1995;6:257-282.
6. Fisher RI, Dahlberg S, Nathwani BN, et al. A clinical analysis of 2 indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including mucosa-associated lymphoid tissue and monocytoid B-cell categories). a Southwest Oncology Group study. Blood. 1995;85:1075-1084.
7. Greiner TC, Moynihan MJ, Chan WC, et al. P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87:4302-4310.
8. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol. 1998;16:3803-3809.
9. Khouri IF, Lee MS, Saliba R, et al. Non-ablative allogeneic stem cell transplantation for advanced/recurrent mantle cell lymphoma. J Clin Oncol. 2003;21:4407-4412.
10. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper- CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013-7023.
11. Stanley KE. Prognostic factors for survival in patients with inoperative lung cancer. J Natl Cancer Inst. 1980;65:25-32.
12. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology. 2000;36:69-86.
13. Luthra R, Sarris AH, Hai S, et al. Real-time 5′ - >3′ exonuclease-based PCR assay for detection of the t(11;14)(q13;q32). Am J Clin Pathol. 1999;112:524-530.
14. Katz RL, Caraway NP, Gu J, et al. Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization. A useful ancillary method for the diagnosis of mantle cell lymphoma. Am J Clin Pathol. 2000;114:248-257.
15. Cheson BD, Horning SJ, Coiffier B, et al. Report on an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;10:1244-1253.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Roy Stat Soc. 1972;135:185-207.
18. Shipp MA; Harrington DP, and the International Non-Hodgkin's Lymphoma Prognostic Factors Project, et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
19. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase 2 study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
20. Gressin R, Legouffe E, Leroux D, et al. Treatment of mantle-cell lymphomas with the VAD ± chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation. Ann Oncol. 1997;8(suppl 1):103-106S.
21. Kaufmann YL, Jones RJ, Diehl LF, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed or refractory mantle cell lymphoma. Blood. 2004;104:2269-2271.
22. Dang NH, Hagemeister FB, Pro B, et al. Phase 2 study of denileukin diftitox for relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:4095-4102.
23. Cohen BJ, Moskowitz C, Strauss D, et al. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma. 2001;42:1015-1022.
24. Goy A, Younes A, McLaughlin P, et al. Phase 2 study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667-675.
25. O'Connor OA, Wright J, Moskowitz C, et al. Phase 2 clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676-684.
26. Mclaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996.;14:1262-1268.
27. Seymour JF, Grigg AP, Szer J, Fox RM. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol. 2001;12:1455-1460.
28. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064-3071.
29. Levine AM, Espina BM, Mohrbacher LH, et al. Fludarabine, mitoxantrone, and rituxan: an effective regimen for the treatment of mantle cell lymphoma [abstract]. Blood. 2002;100(suppl 1):361A.
30. Mathias J. Rummel, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23: 3383-3389.
31. Fisher RI, Bernstein SH, Kahk BS, et al. Multicenter phase 2 study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006.;24:4867-4874.
32. Robak T, Smolewski P, Sebula B, et al. Rituximab combined with cladribine or with cladribina and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer. 2006;107:1542-1550.
33. Rupolo M, Michieli M, Spina M, et al. R-Dhaox, high dose chemotherapy (HDC) and rituximab maintenance as salvage treatment in relapsed or refractory (R/R) follicular (F) and mantle cell (MC) lymphomas (NHL) [abstract]. J Clin Oncol. 2007:100(suppl 18):450S. (Abstract 8036).
34. Drach J, Kaufmann H, Pichelmayer O, et al. Marked activity of bortezomib, rituximab and dexamethasone in relapsed and refractory mantle cell lymphoma [abstract]. Blood. 2006;108:779A.